Chamundeswari Subramanian, MD
Internal Medicine · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 6
- 2 carriers
- Offices
- 3
- Since medical school
- 16 years
- Graduated 2010
Offices
3 locations · County of Santa Clara · 1,000 clinicians in this group
Looking this up.
Hospitals listed: Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
6 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Subramanian’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
6 of 6 plans
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A132766 · Current
Licensed to practise in California · since 2014 · expires 2028-10-31 · Ntr University of Health Sciences, Vijayawada, Deccan College of Medical Sciences.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Internal Medicine
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 80.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$1,845
Medicare paid this office $1,845 for 52 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| X-ray of chest, 2 views | 11 | $210 | $19 |
| Routine electrocardiogram (ecg) using at least 12 leads with tracing | 11 | $41 | $3 |
Who their Medicare patients are
52 Original Medicare patients in 2024. Average age 71 · Women 69% · Health risk score 1.25. At or below the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 67% · Diabetes 50%.
The office billed $33,189, Medicare allowed $2,661 and paid $1,845; for 69 services of 21 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 52 | 69 | 71 | 1.25 | $33,189 | $1,845 |
| 2023 | 22 | 24 | 71 | 1.07 | $11,482 | $828 |
| 2022 | 36 | 46 | 70 | 0.89 | $19,920 | $1,254 |
| 2021 | 30 | 36 | 70 | 1.29 | $14,908 | $729 |
| 2020 | 18 | 24 | 65 | 1.01 | $9,982 | $923 |
| 2019 | 51 | 64 | 68 | 1.56 | $31,189 | $2,040 |
| 2018 | 47 | 61 | 68 | 1.18 | $21,342 | $1,002 |
| 2017 | 44 | 62 | 67 | 1.44 | $13,940 | $643 |
| 2016 | 28 | 52 | 66 | 1.22 | $23,483 | $749 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2019: 2 services
| Short return visit (20+ min) | 11 | $746 | $62 |
| X-ray of chest, 2 views | 15 | $246 | $15 |
Medicaid work
$605,499 in 2024
Medicaid paid $605,499 for 14,079 billed services this clinician did in 2024, up to 173 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 1,128 | $579,414 |
| Federally qualified health center (fqhc) visit, established patient; a medically-necessary, face-to-face encounter (one-on-one) between an established patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a fqhc visit | 28 | $12,970 |
| Short return visit (20+ min) | 2,257 | $4,344 |
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use | 14 | $1,835 |
| Return visit (30+ min) | 370 | $1,331 |
| Thyroid stimulating hormone (TSH) | 194 | $748 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, single dose | 29 | $700 |
| Blood test, lipids (cholesterol and triglycerides) | 262 | $663 |
| Hemoglobin A1C level | 389 | $493 |
| Tuberculosis test, cell mediated immunity antigen response measurement; enumeration of gamma interferon-producing T-cells in cell suspension | 27 | $363 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 401 | $278 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 145 | $271 |
| 2024 | 14,079 | 50 | 173 | $605,499 |
| 2023 | 8,970 | 37 | 151 | $621,057 |
| 2022 | 5,993 | 32 | 120 | $448,726 |
| 2021 | 5,249 | 28 | 136 | $633,410 |
| 2020 | 2,840 | 20 | 126 | $283,554 |
| 2019 | 4,287 | 21 | 142 | $362,760 |
| 2018 | 4,216 | 21 | 156 | $466,907 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 1,232 | $609,385 |
| Short return visit (20+ min) | 2,328 | $5,742 |
| Zoster (shingles) vaccine (HZV), recombinant, subunit, adjuvanted, for intramuscular use | 82 | $1,340 |
| Return visit (30+ min) | 355 | $1,181 |
| Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use | 20 | $693 |
| Hemoglobin A1C level | 312 | $383 |
| Thyroid stimulating hormone (TSH) | 153 | $372 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 104 | $302 |
| Payment for communication technology-based services for 5 minutes or more of a virtual (non-face-to-face) communication between an rural health clinic (rhc) or federally qualified health center (fqhc) practitioner and rhc or fqhc patient, or 5 minutes or more of remote evaluation of recorded video and/or images by an rhc or fqhc practitioner, occurring in lieu of an office visit; rhc or fqhc only | 38 | $281 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 52 | $220 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 474 | $213 |
| Tuberculosis test, cell mediated immunity antigen response measurement; enumeration of gamma interferon-producing T-cells in cell suspension | 16 | $211 |
2022
| Clinic visit/encounter, all-inclusive | 911 | $440,911 |
| Short return visit (20+ min) | 1,519 | $3,418 |
| Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use | 60 | $1,386 |
| Zoster (shingles) vaccine (HZV), recombinant, subunit, adjuvanted, for intramuscular use | 50 | $495 |
| Tuberculosis test, cell mediated immunity antigen response measurement; enumeration of gamma interferon-producing T-cells in cell suspension | 21 | $334 |
| Return visit (30+ min) | 139 | $330 |
| Hemoglobin A1C level | 243 | $268 |
| Short return visit | 81 | $232 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 112 | $220 |
| Blood test, lipids (cholesterol and triglycerides) | 120 | $217 |
| Thyroid stimulating hormone (TSH) | 83 | $213 |
| HEPATITIS C ANTIBODY | 62 | $140 |
2021
| Clinic visit/encounter, all-inclusive | 1,338 | $626,774 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; first dose | 42 | $1,680 |
| Short return visit (20+ min) | 989 | $1,511 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; second dose | 34 | $1,360 |
| Short return visit | 1,130 | $985 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; booster dose | 13 | $520 |
| Return visit (30+ min) | 92 | $203 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 15 | $82 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 15 | $82 |
| Hemoglobin A1C level | 142 | $47 |
| Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result | 27 | $30 |
| Blood test, lipids (cholesterol and triglycerides) | 15 | $28 |
2020
| Clinic visit/encounter, all-inclusive | 864 | $281,856 |
| Short return visit (20+ min) | 760 | $884 |
| Short return visit | 524 | $274 |
| Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique | 12 | $155 |
| Payment for communication technology-based services for 5 minutes or more of a virtual (non-face-to-face) communication between an rural health clinic (rhc) or federally qualified health center (fqhc) practitioner and rhc or fqhc patient, or 5 minutes or more of remote evaluation of recorded video and/or images by an rhc or fqhc practitioner, occurring in lieu of an office visit; rhc or fqhc only | 31 | $114 |
| Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result | 21 | $44 |
| Return visit (30+ min) | 82 | $41 |
| Hemoglobin A1C level | 83 | $37 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 17 | $30 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 17 | $30 |
| ELECTROLYTE PANEL | 74 | $22 |
| Creatinine; blood | 76 | $16 |
2019
| Clinic visit/encounter, all-inclusive | 1,104 | $357,908 |
| Short return visit (20+ min) | 1,156 | $2,912 |
| Return visit (30+ min) | 296 | $903 |
| Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result | 109 | $267 |
| Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use | 99 | $157 |
| Hemoglobin A1C level | 220 | $148 |
| Thyroid stimulating hormone (TSH) | 59 | $115 |
| Blood test, lipids (cholesterol and triglycerides) | 84 | $90 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 221 | $77 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 45 | $35 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 35 | $30 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 34 | $30 |
2018
| Clinic visit/encounter, all-inclusive | 1,469 | $461,610 |
| Short return visit (20+ min) | 1,171 | $3,991 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 98 | $238 |
| Thyroid stimulating hormone (TSH) | 86 | $166 |
| Return visit (30+ min) | 46 | $162 |
| Federally qualified health center (fqhc) visit, established patient; a medically-necessary, face-to-face encounter (one-on-one) between an established patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a fqhc visit | 68 | $160 |
| Blood test, lipids (cholesterol and triglycerides) | 67 | $91 |
| Hemoglobin A1C level | 113 | $83 |
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 12 | $74 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 197 | $63 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 16 | $60 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 15 | $60 |
Drugs they prescribed that Part D paid
$104,856
Pharmacies billed $104,856 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 1% of their Part D prescriptions (15 of 1,500) in 2024. At or below the middle of the specialty; the typical internal medicine clinician is at 1%.
1,328 generic and fewer than 11 brand-name prescriptions · $104,856 in drug cost · 54 antibiotic prescriptions to 47 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Trulicity | 16 | $22,294 | $1,393 |
| Jardiance | 15 | $21,718 | $1,448 |
| Eliquis | 11 | $7,416 | $674 |
| Arnuity Ellipta | 11 | $2,032 | $185 |
| Sps | 16 | $1,972 | $123 |
See all 38 drugs
| Trulicity | 16 | $22,294 | $1,393 |
| Jardiance | 15 | $21,718 | $1,448 |
| Eliquis | 11 | $7,416 | $674 |
| Arnuity Ellipta | 11 | $2,032 | $185 |
| Sps | 16 | $1,972 | $123 |
| Gabapentin | 66 | $1,061 | $16 |
| Albuterol Sulfate Hfa | 32 | $1,052 | $33 |
| Atorvastatin | 161 | $950 | $6 |
| Diclofenac | 26 | $527 | $20 |
| Levothyroxine | 45 | $408 | $9 |
| Lisinopril | 42 | $404 | $10 |
| Losartan | 56 | $353 | $6 |
| Duloxetine | 17 | $351 | $21 |
| Amlodipine Besylate | 118 | $323 | $3 |
| Omeprazole | 55 | $230 | $4 |
| Pantoprazole | 37 | $214 | $6 |
| Metoprolol | 21 | $210 | $10 |
| Furosemide | 44 | $192 | $4 |
| Metformin | 39 | $188 | $5 |
| Metformin Hcl Er | 16 | $178 | $11 |
| Tamsulosin | 23 | $176 | $8 |
| Fluticasone Propionate | 16 | $159 | $10 |
| Montelukast | 19 | $143 | $8 |
| Isosorbide Mononitrate Er | 15 | $139 | $9 |
| Finasteride | 13 | $131 | $10 |
| Nitrofurantoin Mono-Macro | 14 | $128 | $9 |
| Carvedilol | 15 | $102 | $7 |
| Metoprolol | 22 | $94 | $4 |
| Alendronate | 18 | $94 | $5 |
| Ibuprofen | 33 | $93 | $3 |
| Famotidine | 14 | $89 | $6 |
| Gemfibrozil | 11 | $87 | $8 |
| Hydrochlorothiazide | 42 | $86 | $2 |
| Glipizide | 16 | $76 | $5 |
| Atenolol | 26 | $71 | $3 |
| Simvastatin | 12 | $61 | $5 |
| Triamcinolone Acetonide | 11 | $48 | $4 |
| Cephalexin | 11 | $46 | $4 |
Year by year
| 2024 | 1,500 | 213 | 1% (15) | None | $104,856 |
| 2023 | 1,375 | 210 | 2% (20) | None | $123,306 |
| 2022 | 1,027 | 210 | 2% (19) | None | $74,488 |
| 2021 | 828 | 149 | 2% (13) | 13% | $50,565 |
| 2020 | 723 | 103 | None | 15% | $39,891 |
| 2019 | 903 | 165 | 3% (31) | None | $38,907 |
| 2018 | 682 | 197 | 2% (14) | None | $27,160 |
| 2017 | 670 | 206 | 4% (24) | None | $21,455 |
| 2016 | 468 | 198 | 5% (21) | None | $13,227 |
| 2015 | 76 | 32 | None | None | $2,369 |
| 2014 | 16 | None | 0% (0) | None | $760 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 33 drugs
| Trulicity | 17 | $25,818 | $1,519 |
| Jardiance | 12 | $17,658 | $1,472 |
| Atorvastatin | 174 | $4,001 | $23 |
| Gabapentin | 59 | $1,247 | $21 |
| Amlodipine Besylate | 104 | $1,170 | $11 |
| Ventolin Hfa | 16 | $882 | $55 |
| Isosorbide Dinitrate | 13 | $766 | $59 |
| Levothyroxine | 43 | $746 | $17 |
| Losartan | 41 | $681 | $17 |
| Pantoprazole | 40 | $637 | $16 |
| Lisinopril | 37 | $540 | $15 |
| Metformin | 43 | $526 | $12 |
| Diclofenac | 25 | $461 | $18 |
| Atenolol | 15 | $443 | $30 |
| Carvedilol | 22 | $405 | $18 |
| Famotidine | 15 | $404 | $27 |
| Duloxetine | 17 | $391 | $23 |
| Alendronate | 14 | $390 | $28 |
| Albuterol Sulfate Hfa | 12 | $372 | $31 |
| Clopidogrel | 11 | $314 | $29 |
| Metoprolol | 15 | $297 | $20 |
| Fluticasone Propionate | 23 | $248 | $11 |
| Furosemide | 32 | $238 | $7 |
| Simvastatin | 14 | $233 | $17 |
| Baclofen | 26 | $213 | $8 |
| Omeprazole | 19 | $190 | $10 |
| Metoprolol | 16 | $189 | $12 |
| Cephalexin | 15 | $181 | $12 |
| Glipizide | 11 | $161 | $15 |
| Hydrochlorothiazide | 34 | $154 | $5 |
| Naproxen | 19 | $122 | $6 |
| Triamcinolone Acetonide | 16 | $115 | $7 |
| Ibuprofen | 11 | $61 | $6 |
2022: 26 drugs
| Atorvastatin | 111 | $2,051 | $18 |
| Gabapentin | 36 | $876 | $24 |
| Amlodipine Besylate | 81 | $855 | $11 |
| Ventolin Hfa | 15 | $818 | $55 |
| Losartan | 30 | $616 | $21 |
| Levothyroxine | 28 | $603 | $22 |
| Albuterol Sulfate Hfa | 14 | $557 | $40 |
| Atenolol | 17 | $325 | $19 |
| Metoprolol | 13 | $308 | $24 |
| Alendronate | 16 | $273 | $17 |
| Fluticasone Propionate | 27 | $242 | $9 |
| Glipizide | 16 | $216 | $13 |
| Carvedilol | 20 | $200 | $10 |
| Lisinopril | 27 | $182 | $7 |
| Baclofen | 17 | $180 | $11 |
| Omeprazole | 20 | $168 | $8 |
| Hydrochlorothiazide | 35 | $164 | $5 |
| Furosemide | 21 | $155 | $7 |
| Pantoprazole | 19 | $153 | $8 |
| Metformin | 25 | $137 | $5 |
| Hydrocodone-Acetaminophen | 11 | $131 | $12 |
| Benazepril | 14 | $128 | $9 |
| Naproxen | 14 | $87 | $6 |
| Triamcinolone Acetonide | 14 | $67 | $5 |
| Ibuprofen | 19 | $63 | $3 |
| Cephalexin | 11 | $62 | $6 |
2021: 23 drugs
| Atrovent Hfa | 11 | $4,961 | $451 |
| Atorvastatin | 66 | $1,199 | $18 |
| Ventolin Hfa | 11 | $633 | $58 |
| Gabapentin | 39 | $610 | $16 |
| Levothyroxine | 19 | $549 | $29 |
| Baclofen | 22 | $454 | $21 |
| Amlodipine Besylate | 50 | $378 | $8 |
| Fluticasone Propionate | 30 | $309 | $10 |
| Losartan | 25 | $308 | $12 |
| Omeprazole | 30 | $184 | $6 |
| Pantoprazole | 23 | $177 | $8 |
| Glipizide | 23 | $144 | $6 |
| Allopurinol | 12 | $138 | $12 |
| Lisinopril | 24 | $127 | $5 |
| Carvedilol | 13 | $111 | $9 |
| Furosemide | 19 | $104 | $5 |
| Triamcinolone Acetonide | 17 | $95 | $6 |
| Cephalexin | 13 | $94 | $7 |
| Metformin | 23 | $92 | $4 |
| Tamsulosin | 15 | $76 | $5 |
| Hydrochlorothiazide | 21 | $72 | $3 |
| Naproxen | 14 | $51 | $4 |
| Simvastatin | 14 | $43 | $3 |
2020: 25 drugs
| Atrovent Hfa | 22 | $9,195 | $418 |
| Pulmicort Flexhaler | 13 | $2,197 | $169 |
| Ventolin Hfa | 15 | $865 | $58 |
| Gabapentin | 22 | $701 | $32 |
| Atorvastatin | 59 | $648 | $11 |
| Levothyroxine | 18 | $639 | $35 |
| Baclofen | 18 | $367 | $20 |
| Pantoprazole | 19 | $356 | $19 |
| Fosinopril | 14 | $343 | $25 |
| Fluticasone Propionate | 28 | $323 | $12 |
| Losartan | 29 | $224 | $8 |
| Amlodipine Besylate | 45 | $173 | $4 |
| Allopurinol | 11 | $172 | $16 |
| Metformin | 23 | $165 | $7 |
| Lisinopril | 21 | $138 | $7 |
| Atenolol | 19 | $132 | $7 |
| Glipizide | 12 | $130 | $11 |
| Omeprazole | 18 | $116 | $6 |
| Carvedilol | 12 | $110 | $9 |
| Furosemide | 12 | $70 | $6 |
| Ibuprofen | 23 | $61 | $3 |
| Simvastatin | 16 | $57 | $4 |
| Tamsulosin | 12 | $52 | $4 |
| Hydrochlorothiazide | 13 | $29 | $2 |
| Metoprolol | 11 | $23 | $2 |
2019: 30 drugs
| Atrovent Hfa | 13 | $4,788 | $368 |
| Duloxetine | 21 | $1,058 | $50 |
| Levothyroxine | 23 | $717 | $31 |
| Atorvastatin | 52 | $636 | $12 |
| Fluticasone Propionate | 32 | $354 | $11 |
| Gabapentin | 19 | $337 | $18 |
| Amlodipine Besylate | 45 | $318 | $7 |
| Pantoprazole | 17 | $293 | $17 |
| Tamsulosin | 23 | $287 | $12 |
| Gemfibrozil | 15 | $276 | $18 |
| Finasteride | 13 | $268 | $21 |
| Fosinopril | 12 | $261 | $22 |
| Glipizide | 25 | $256 | $10 |
| Metformin | 37 | $255 | $7 |
| Carvedilol | 15 | $193 | $13 |
| Losartan | 29 | $193 | $7 |
| Atenolol | 26 | $182 | $7 |
| Cyclobenzaprine | 18 | $170 | $9 |
| Omeprazole | 18 | $168 | $9 |
| Lisinopril | 31 | $166 | $5 |
| Azithromycin | 19 | $163 | $9 |
| Baclofen | 15 | $155 | $10 |
| Acetaminophen-Codeine | 14 | $123 | $9 |
| Medroxyprogesterone Acetate | 12 | $107 | $9 |
| Simvastatin | 18 | $90 | $5 |
| Benazepril | 12 | $84 | $7 |
| Metoprolol | 17 | $82 | $5 |
| Hydrochlorothiazide | 19 | $73 | $4 |
| Ibuprofen | 15 | $50 | $3 |
| Fluoxetine | 11 | $35 | $3 |
2018: 19 drugs
| Polyethylene Glycol 3350 | 12 | $1,104 | $92 |
| Duloxetine | 11 | $904 | $82 |
| Atorvastatin | 36 | $420 | $12 |
| Fluticasone Propionate | 41 | $390 | $10 |
| Levothyroxine | 15 | $350 | $23 |
| Gabapentin | 22 | $230 | $10 |
| Tamsulosin | 16 | $218 | $14 |
| Pantoprazole | 19 | $217 | $11 |
| Amlodipine Besylate | 31 | $188 | $6 |
| Atenolol | 20 | $150 | $7 |
| Metoprolol | 27 | $135 | $5 |
| Metformin | 22 | $131 | $6 |
| Triamcinolone Acetonide | 12 | $123 | $10 |
| Omeprazole | 23 | $114 | $5 |
| Ibuprofen | 27 | $98 | $4 |
| Losartan | 18 | $95 | $5 |
| Simvastatin | 14 | $81 | $6 |
| Lisinopril | 12 | $76 | $6 |
| Hydrochlorothiazide | 14 | $70 | $5 |
2017: 21 drugs
| Ventolin Hfa | 15 | $700 | $47 |
| Fluticasone Propionate | 37 | $410 | $11 |
| Atorvastatin | 22 | $250 | $11 |
| Amitriptyline | 16 | $193 | $12 |
| Fosinopril | 11 | $192 | $17 |
| Omeprazole | 27 | $187 | $7 |
| Pantoprazole | 11 | $175 | $16 |
| Metformin | 29 | $151 | $5 |
| Losartan | 16 | $140 | $9 |
| Gabapentin | 19 | $138 | $7 |
| Metoprolol | 25 | $129 | $5 |
| Atenolol | 13 | $115 | $9 |
| Ibuprofen | 34 | $102 | $3 |
| Amoxicillin | 17 | $86 | $5 |
| Amlodipine Besylate | 23 | $85 | $4 |
| Clonidine | 11 | $83 | $8 |
| Simvastatin | 21 | $80 | $4 |
| Acetaminophen-Codeine | 11 | $71 | $6 |
| Furosemide | 16 | $62 | $4 |
| Azithromycin | 11 | $58 | $5 |
| Hydrochlorothiazide | 11 | $38 | $3 |
2016: 11 drugs
| Fluticasone Propionate | 44 | $356 | $8 |
| Amlodipine Besylate | 23 | $159 | $7 |
| Omeprazole | 17 | $85 | $5 |
| Ibuprofen | 26 | $84 | $3 |
| Azithromycin | 13 | $83 | $6 |
| Gabapentin | 11 | $65 | $6 |
| Cephalexin | 11 | $60 | $5 |
| Amoxicillin | 12 | $49 | $4 |
| Prednisone | 12 | $36 | $3 |
| Tramadol | 11 | $34 | $3 |
| Lisinopril | 11 | $27 | $2 |
Professional record
- NPI
- 1497016869
- Licence
- CA A132766California A132766: Current · expires 2028-10-31
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Internal medicine (207R00000X)
- Mailing address
- 255 Huguenot St, Apartment 217, New Rochelle, NY, 10801
- NPI first listed
- 2012-06-01
- NPI last updated
- 2023-11-01
- NPI record certified
- 2023-11-01
This is when the NPI record was last certified, not a medical board exam.